Aspirin and recurrent venous thromboembolism

Phlebology

Volumn 28, Issue 1_suppl, 2013, Pages 99-104

  Prandoni, P ^a   Noventa, F ^a   Milan, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

anticoagulation; aspirin; atherosclerosis; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; DIPYRIDAMOLE; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; METHODOLOGY; PATIENT SELECTION; SECONDARY PREVENTION;

ANTICOAGULANTS; ASPIRIN; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PATIENT SELECTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84883195671     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1177/0268355512475040     Document Type: Review

References (33)

1. Antitrombotic Trialists' Combination. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86
2. Falck-Ytter Y, Francis CW, Johanson NA. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.): e278S–325S
3. Gould MK, Garcia DA, Wren SM. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.): e227S–77S
4. Kahn SR, Lim W, Dunn AS. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.):el95S–226S
5. Kearon C, Akl EA, Comerota AJ. Antithrombotic therapy for VTE disease: ntithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl): e419S–94S
6. Douketis JD, Shu GuC, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 147: 766–74
7. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. A meta-analysis. Ann Intern Med 2003; 139: 893–900
8. Carrier M, Le GalG, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578–89
9. Ridker PM, Goldhaber SZ, Danielson E. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425–34
10. Kearon C, Ginsberg JS, Kovacs MJ. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631–9
11. Prandoni P, Lensing AWA, Prins MH. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955–60
12. Piovella F, Crippa L, Barone M. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002; 87: 515–22
13. Prandoni P, Prins MH, Lensing AWA. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009; 150: 577–85
14. Siragusa S, Malato A, Anastasio R. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the “DACUS” study. Blood 2008; 112: 511–5
15. Verhovsek M, Douketis JD, Yi Q. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149: 481–90
16. Palareti G, Cosmi B, Legnani C. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780–9
17. Cosmi B, Legnani C, Tosetto A. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 2010; 115: 481–8
18. Stain M, Schönauer V, Minar E. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost 2005; 3: 2671–6
19. Rodger MA, Kahn SR, Wells PS. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417–26
20. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism. The Vienna Prediction Model. Circulation 2010; 121: 1630–6
21. The Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–510
22. Schulman S, Kearon C, Kakkar AK. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–52
23. Prandoni P, Noventa F, Ghirarduzzi A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. Haematologica 2007; 91: 199–205
24. Schulman S, Granqvist S, Holmstrom M. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336: 393–8
25. Hovens MM, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006; 4: 1470–5
26. Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet 1980; 2: 1328–9
27. Prandoni P, Piovella C, Pesavento R. Venous thromboembolism and arterial complications. Semin Respir Crit Care Med 2012; 33: 205–10
28. Becattini C, Agnelli G, Schenone A. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959–67
29. Brighton TA, Eikelboom JW, Mann K. The ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979–87
30. Prandoni P, Ghirarduzzi A, Prins MH. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006; 4: 1891–6
31. Milan M, Noventa F, Ghirarduzzi A. Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis. Retrospective cohort study. J Thromb Haemost 2012; 10: 2205–6
32. Sørensen HT, Horvath-Puho E, Søgaard KK. Arterial cardiovascular events, statins, low dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009; 7: 521–8
33. Paikin JS, Wright DS, Eikelboom JW. Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials. Blood Rev 2011; 25: 23–9